Hims & Hers Semaglutide Pill Was Never Likely to Pass Muster -- Market Talk
Dow Jones
Feb 09
0715 ET - Hims & Hers has backtracked on plans to release a compounded semaglutide pill following threats from the FDA and DOJ, raising questions about why it tried to push forward in the first place, say Morgan Stanley analysts. "Even before FDA and DOJ involvement, feedback was nearly unanimous that this move was aggressive and would not likely stand up," the analysts say. There could now be increased scrutiny on compounded GLP-1 injectables. "While compounding is permitted under limited circumstances, regulators have cautioned that marketing compounded products in a manner that implies comparable effects to FDA-approved drugs may be misleading," the analysts say. (nicholas.miller@wsj.com)
(END) Dow Jones Newswires
February 09, 2026 07:15 ET (12:15 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.